Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, Chen ZH, Yan HH, Song Y, Chen JH, Feng WN, Xu CR, Wang Z, Chen HJ, Zhong WZ, Liu YP, Wu YL. Zhou Q, et al. Among authors: yang jj. Ann Oncol. 2014 Dec;25(12):2385-2391. doi: 10.1093/annonc/mdu463. Epub 2014 Oct 3. Ann Oncol. 2014. PMID: 25281710 Free article. Clinical Trial.
Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study.
Huang J, Zhang XH, Cai Y, Yang D, Shi J, Xing P, Xu T, Wu L, Su W, Xu R, Wei T, Chen HJ, Yang JJ. Huang J, et al. Among authors: yang d, yang jj. Clin Oncol (R Coll Radiol). 2024 Jan;36(1):39-45. doi: 10.1016/j.clon.2023.11.030. Epub 2023 Nov 11. Clin Oncol (R Coll Radiol). 2024. PMID: 37977903 Clinical Trial.
DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
Escherich CS, Moriyama T, Li Z, Hsiao Y, Yang W, Li Y, Reyes N, Walker M, Budhraja A, Bhatara S, Diaz-Flores E, Stock W, Paietta E, Konopleva MY, Kornblau SM, Litzow MR, Inaba H, Pui CH, Opferman JT, Loh ML, Yu J, O'Brien M, Evans WE, Yang JJ. Escherich CS, et al. Among authors: yang jj. Blood. 2024 Dec 27:blood.2024026085. doi: 10.1182/blood.2024026085. Online ahead of print. Blood. 2024. PMID: 39791601
Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL.
Zhang W, Cai J, Wang X, Ma Y, Zhu X, Yu J, Xiao P, Gao J, Fang Y, Liang C, Li X, Zhou F, Zhai X, Xu X, Tian X, Liu A, Wang N, Zhu J, Wang L, Cheng FWT, Yang L, Zhang G, Cheng C, Yang JJ, Shen S, Li CK, Li B, Jiang H, Pui CH. Zhang W, et al. Among authors: yang jj. Blood. 2024 Dec 30:blood.2024026381. doi: 10.1182/blood.2024026381. Online ahead of print. Blood. 2024. PMID: 39786460
2,324 results